key: cord-1017746-8oigpg5b
authors: Foy, B. H.; Wahl, B.; Mehta, K.; Shet, A.; Menon, G. I.; Britto, C. D.
title: Comparing COVID-19 vaccine allocation strategies in India: a mathematical modelling study
date: 2020-11-24
journal: nan
DOI: 10.1101/2020.11.22.20236091
sha: ac48ad38e554e67c1378aa2fb14a655a76b4db43
doc_id: 1017746
cord_uid: 8oigpg5b

Background: The development and widespread use of an effective SARS-CoV-2 vaccine could help prevent substantial morbidity and mortality associated with COVID-19 infection and mitigate many of the secondary effects associated with non-pharmaceutical interventions. The limited availability of an effective and licensed vaccine will task policymakers around the world, including in India, with decisions regarding optimal vaccine allocation strategies. Using mathematical modelling we aimed to assess the impact of different age-specific COVID-19 vaccine allocation strategies within India on SARS CoV-2-related mortality and infection. Methods: We used an age-structured, expanded SEIR model with social contact matrices to assess different age-specific vaccine allocation strategies in India. We used state-specific age structures and disease transmission coefficients estimated from confirmed Indian incident cases of COVID-19 between 28 January and 31 August 2020. Simulations were used to investigate the relative reduction in mortality and morbidity of vaccinate allocation strategies based on prioritizing different age groups, and the interactions of these strategies with several concurrent non-pharmacologic interventions (i.e., social distancing, mandated masks, lockdowns). Given the uncertainty associated with current COVID-19 vaccine development, we also varied several vaccine characteristics (i.e., efficacy, type of immunity conferred, and rollout speed) in the modelling simulations. Results: In nearly all scenarios, prioritizing COVID-19 vaccine allocation for older populations (i.e., >60yrs old) led to the greatest relative reduction in deaths, regardless of vaccine efficacy, control measures, rollout speed, or immunity dynamics. However, preferential vaccination of this target group often produced higher total symptomatic infection counts and more pronounced estimates of peak incidence than strategies which targeted younger adults (i.e., 20-40yrs or 40-60yrs) or the general population irrespective of age. Vaccine efficacy, immunity type, target coverage and rollout speed all significantly influenced overall strategy effectiveness, with the time taken to reach target coverage significantly affecting the relative mortality benefit comparative to no vaccination. Conclusions: Our findings support global recommendations to prioritize COVID-19 vaccine allocation for older age groups. Including younger adults in the prioritisation group can reduce overall infection rates, although this benefit was countered by the larger mortality rates in older populations. Ultimately an optimal vaccine allocation strategy will depend on vaccine characteristics, strength of concurrent non-pharmaceutical interventions, and region-specific goals such as reducing mortality, morbidity, or peak incidence.

Our findings support global recommendations to prioritize COVID-19 vaccine allocation for older age groups. Including younger adults in the prioritisation group can reduce overall infection rates, although this benefit was countered by the larger mortality rates in older populations.

Ultimately an optimal vaccine allocation strategy will depend on vaccine characteristics, strength of concurrent non-pharmaceutical interventions, and region-specific goals such as reducing mortality, morbidity, or peak incidence.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 

After first emerging in Wuhan, China in late 2019, (Li et al. 2020) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 , has spread rapidly throughout the world causing local epidemics in virtually all countries (Dong et al. 2020) . The virus is spread primarily through respiratory droplets and close contact with infected individuals (Chan et al. 2020; Li et al. 2020) . While early, large-scale COVID-19 epidemics occurred primarily in high-income countries in Europe and North America, a significant number of cases and deaths attributable to the virus have also now occurred in low-and middle-income countries (Dong et al. 2020 ). Approximately 1.4 billion people are at risk of SARS-CoV-2 infection in India with many having risk factors for severe outcomes (Nandi et al. 2020 ).

The first confirmed case of COVID-19 in India was identified in Kerala on 30 January, 2020 in an Indian national who returned from China (Perappadan 2020) . During the following month-and-a-half, several travel-associated cases were confirmed throughout the country (Rawat 2020) . To slow the spread of the virus and reduce peak incidence, the central government initiated one of the largest lockdowns in the world on 25 March 2020 comprising several non-pharmaceutical interventions (NPIs), including physical distancing and restrictions on non-essential travel (Pulla 2020) . Several analyses have indicated that lockdown measures reduced the effective reproduction number ( ) in the country (Gupta et al. 2020; Kumar et al. 2020; Sardar et al. 2020) . However, the lockdown precipitated several secondary effects, including reduced livelihoods, difficulties with accessing routine health services, and mass migrations (The Lancet 2020). Lockdown measures were relaxed beginning on 1 June 2020 and as of 12 November 2020, India has reported approximately 8.6 million cases and 130,000 deaths (Dong et al. 2020 ).

In the absence of a highly effective therapeutic agent for COVID-19, the development of vaccines that provide protection from SARS-CoV-2 infection is a global imperative. An unprecedented effort is currently underway to rapidly develop effective COVID-19 vaccines, with several stakeholders working together to compress a process that normally takes years or decades into months (Graham . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 https://doi.org/10. .11.22.20236091 doi: medRxiv preprint 2020 vaccines. Through this mechanism, 92 low-and middle-income countries, including India, are eligible to be supported by the COVAX Advance Market Commitment (AMC), which will pay for the cost of COVID-19 vaccines once COVID-19 vaccines have been licensed and prequalified by the WHO.

Based on WHO guidelines and recommendations related to which priority groups should receive COVID-19 vaccines first (World Health Organization 2020b), countries participating in the COVAX Facility are encouraged to prioritize frontline health workers and social care workers. Toward that end, the mechanism aims to distribute COVID-19 vaccines equally to countries until they have achieved a sufficient supply to protect this vulnerable population, determined to represent approximately 3% of country populations. As the supply of COVID-19 vaccines increases, the distribution of COVID-19 vaccines through the COVAX Facility will continue such that 20% of country populations can be covered, specifically those at increased risk (i.e., older adults and those who have underlying health conditions).

In the context of limited supply and to support policies related to COVID-19 vaccine allocation in India, we developed a mathematical model to simulate different vaccine allocation strategies. There is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 remain several unknowns associated with the current COVID-19 vaccine development. Therefore, we assessed these vaccine allocation strategies varying potential vaccine characteristics. We also evaluated the relative reduction in cases and deaths in the context of varying control measures (NPIs).

The findings of this analysis could also be used by other low-and middle-income countries to inform their COVID-19 vaccine allocation strategies.

Daily and state-specific incident SARS-CoV-2 infection case data were collected from multiple sources, including the Ministry of Health and Family Welfare (MOHFW), the Indian Council of Medical Research (ICMR), and a website for crowd-sourced information related to COVID-19 in India (www.covid19india.com). The data available from this website are collated from public sources and validated by a group of volunteers.

Disease transmission in Indian populations was modelled using an age-structured compartment model, stratified into ten-year age bands (0-10, 10-20, […], 60-70, ≥70 years). The model includes different compartments for each age band and infection state (i.e., , , , , , and ). We assume subjects start off susceptible to infection ( ) and can become exposed ( ) after contact with an infectious individual. After a latent period, exposed subjects either develop an asymptomatic ( ) or symptomatic ( ) infection, with an age-stratified probability. Subjects with symptomatic infections are either hospitalized or choose to self-isolate ( ) at a given rate. Once hospitalized or isolated, subjects either recover ( ) or die ( ), with an age-stratified mortality rate. Asymptomatic individuals are assumed to have no risk of mortality and simply recover at a given rate. Recovered subjects are assumed to become susceptible at a given rate, reflecting eventual loss of temporary immunity from the infection (Sariol and Perlman 2020) . We assumed that COVID-19 vaccines are allocated gradually into a specific age-defined community at a constant rate. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10. 1101 We simulated two different mechanism through which COVID-19 vaccines could induce immunity (Peiris and Leung 2020) . In one simulation, vaccinated individuals ( ) are protected from infection and therefore unable to infect others if exposed to an infected individual (i.e., sterilizing immunity). In the other simulation, vaccinated individuals are not protected from asymptomatic infection if exposed and therefore can infect others if they become infected (i.e., non-sterilizing immunity). In the latter, if an individual develops an asymptomatic infection after receiving a vaccine that does not confer sterilizing immunity, they are assumed to have a temporary immunity from developing further asymptomatic infections, with immunity waning at the same rate as non-vaccinated subjects who recover from infection. Formulated as a system of differential equations, and using to denote the susceptible population from age group , for each age group our model comprises: is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236091 doi: medRxiv preprint

where 1/ is the average length of immunity, 1 is the force of infection, is the total population size, 1/ is the average latent period, is the proportion of infections which are symptomatic, 1/ is the average asymptomatic recovery time, 1/ is the average time from isolation to recovery for a symptomatic infection, 1/ is the average time until a symptomatically infectious subject selfquarantines or is hospitalized, and is the likelihood of death given symptomatic infection. is the relative frequency of contact between age group and age group . For the simulation where vaccines confer non-sterilizing immunity, 2 = 1 and , , and denote subjects who are exposed, asymptomatic, and recovered, respectively. For the simulation where COVID-19 vaccines provide sterilizing immunity, 2 = 0, meaning those who are vaccinated cannot become infectious. In both cases, vaccines are assumed to be rolled out gradually, with doses available each day, and an efficacy of . A flow diagram of transitions within the model is given in Figure 1 .

Contact matrices ( ) were estimated from social mixing patterns in the general Indian population (Prem et al. 2017) . Estimates were broken down into four mixing categories, representing the four mixing patterns in different environments: (1) "at home", (2) "at school", (3) "at work", and (4) "other"; with representing the summation of the four mixing matrices. In normal scenarios (i.e., no control measures), each mixing pattern was equally weighted. Under strong control measures weights of 1.21, 0.56, 0.0, and 0.45 were used for "at home", "at work", "at school", and "other" matrices respectively, based on estimates from Google's mobility data during the lockdown period (March 25 -May 31, 2020) (Aktay et al. 2020) . Moderate control measures were simulated using the average between no control and strong control measure weights.

All parameters except were estimated based on prior studies, with a full list of parameters, estimated values, and their sources given in Table 1 . values were estimated based on fits of the model-simulated, hospitalized or self-isolated population numbers ( ) against confirmed active . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10. 1101 infection case numbers, between 1 June and 31 July (i.e., after the lockdown period). Given variability in social mixing patterns immediately after the national lockdown, values were estimated assuming moderate control measures and no control measures during this period. Parameter fitting was performed using MATLAB's Statistical Toolbox with an example data fit presented in the supplemental materials. All models were simulated in MATLAB and use forward Euler discretisation for the differential equations, with a timestep of one day.

Four age-based vaccination strategies were considered: (1) vaccines are distributed evenly across the entire population or were first distributed to those who were: (2) 20-40 years, (3) 40-60 years, or (4) ≥60 years. In strategies 2-4, following vaccination of the target age group to the assumed vaccine coverage, vaccine doses were allocated evenly to the remaining population. Simulations were performed using a range of vaccine efficacies, and assuming a fixed number of doses available each day. For each age group, total vaccinations were set to not exceed the target coverage of the population, reflecting that many people will not be vaccinated, due to personal choice or local availability limitations.

Within this framework, simulations were performed using efficacy and target coverage ranging from 0-100% and considering vaccines that provide sterilizing and non-sterilizing immunity. Dose availability was assumed constant over time, reflecting the market pressures of acquiring vaccine doses, and the logistic pressures of distributing these doses. Dose availability was expressed as the percentage of the population which could be vaccinated each month, with simulations using values from 2-15%, reflecting an approximate time of between six months to four years to vaccinate to 100% of the target population. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236091 doi: medRxiv preprint

To capture region specific infection dynamics, 0 values were estimated for the 10 most populous states within India, assuming moderate control measures and no control measures. Estimates are given in Table 1 , with mean 0 values of 2.4 assuming no control measures and 3.2 assuming moderate control measures during the lockdown period. We used the former estimate as the base case value in our simulations. Minimum and maximum values were 1.8 and 5.0 respectively, with results using these values presented in the supplemental materials. The values in Table 1 are consistent with 0 values reported for other countries (Gatto et al. 2020; Sanche et al. 2020; Wu et al. 2020; Zhao et al. 2020 ). Within our model, the implementation of moderate and severe control measures led to a 23% and 44% relative reduction in 0 , respectively.

Four vaccine strategies were simulated under variations in dosage availability, target group coverage, vaccine efficacy, effect on transmission (i.e., sterilizing or non-sterilizing immunity), and the implementation of other control measures (i.e., no lockdown, moderate lockdown, or strong lockdown). Example epidemic curves for COVID-19 vaccines that confer sterilizing and nonsterilizing immunity are given in Figure 2 . Regardless of vaccination strategy and immunization coverage in the target population, the initial infection wave occurs at a similar time, though with varying severity based on strategy. However, COVID-19 vaccines that confer sterilizing immunity appear to minimize the extent of future infection waves. In both cases strategy 4 (i.e., prioritizing individual ≥60 years) leads to the greatest reduction in deaths; however, all vaccination strategies produce significant benefits comparative to no vaccination.

Within Figure 3 , we present the estimated reduction in deaths and symptomatic infections over a five-

year period using each of the four vaccination strategies, under varying efficacy, control measures, and rollout speeds. All results are presented relative to the outcomes with no vaccination, using the . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. same 0 value, and with no control measures. Simulations were performed using an 0 of 2.4 (i.e., the mean 0 value in 10 states) and assume a target COVID-19 vaccine coverage of 75%. Results in Figure 3 illustrate that prioritizing vaccine allocation among older adults consistently results in the greatest reduction in deaths, regardless of vaccine efficacy, control measures, rollout speed, or immunity type. Conversely, all four strategies result in extremely similar reductions in symptomatic infection rates, with the optimal strategy being dependent on the specific implementation and vaccine.

The relative benefit of prioritizing vaccine allocation among older adults compared to other strategies is highest under slower rollout speeds, while overall benefit is greatest the faster the rollout speed.

Overall reduction in deaths is strongly limited by vaccine efficacy, and is strongly influenced by control measures, with more severe measures leading to greater reductions. Similar patterns were seen with different 0 values and target coverages (supplemental materials). Similar patterns were also seen when assuming imperfect self-isolation of symptomatically infectious individuals (supplemental materials).

While 0 values, vaccine efficacy, and other vaccine characteristics (i.e., sterilizing versus nonsterilizing immunity) all influence strategy effectiveness, in application these factors are immutable from the perspective of policy makers. Rather, international and national efforts, including investments and policies, can primarily influence three factors: (1) dosage availability/rollout speed,

(2) target vaccine coverage; and (3) the continuation or relaxation of control measures. Within this context, in Figure 4 we present the relative reduction in deaths for vaccine allocation prioritizing older adults as each of those factors is modified. Equivalent results for strategies 1-3 are presented in the supplemental materials. Under low coverage, the speed at which the vaccine is rolled out has little effect on the overall reduction in deaths.

The findings of our models support international recommendations to prioritize COVID-19 vaccine allocation for older adults (World Health Organization 2020b). Our model indicated that prioritizing vaccine allocation in older populations will contribute to the greatest relative reduction in mortality in . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10. 1101 all scenarios considered in our model. Our analyses indicate that prioritising younger populations will have a greater impact on reducing incidence of infections relative to prioritizing older age groups.

However, this reduction is marginal and prioritizing younger age groups will contribute the lowest relative reduction on COVID-19 mortality compared to other vaccine allocation strategies, including equal distribution to the general population. These findings were consistent, although to different degrees, across all model iterations, including COVID-19 vaccines that confer sterilizing and nonsterilizing immunity. A similar framework for equitable allocation of COVID-19 vaccine that prioritised older populations was adopted by the panel of experts from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH) and the National Academies (Gayle et al. 2020 ).

Leung 2020). However, it is unlikely that leading vaccine candidates will provide 100% protective efficacy or protection from asymptomatic carriage. For this reason, we varied vaccine efficacy and the type of immune response conferred by COVID-19 vaccines in our models. Most candidate vaccines that are currently in Phase III trials aim to assess efficacy against clinical disease (Peiris and Leung 2020). Recent reports of preliminary analyses from leading COVID-19 vaccine candidates in advanced phases of clinical development indicate vaccine efficacy against confirmed cases of >90%, including among older populations (Callaway 2020) . The WHO has indicated that a successful vaccine should be 50% efficacious with the lower bound of 95% confidence intervals not crossing below 30% (Krause et al. 2020) . We observed greater differences between COVID-19 vaccine allocation strategies at higher vaccine efficacy values for relative reductions in deaths. Vaccines that confer sterilizing immunity led to greater relative reductions of cases and deaths compared to vaccine that did not provide sterilizing immunity. This is attributable to the fact that sterilizing vaccines contribute to disrupting transmission of the virus. However, it should be noted that COVID-19 vaccine challenge studies in primates have demonstrated reductions in symptomatic disease and viral load, but did not produce sterilising immunity (Corbett et al. 2020; van Doremalen et al. 2020 ). Some is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236091 doi: medRxiv preprint first-generation COVID-19 vaccines that reduce disease severity, might not effectively reduce SARS-

Policy makers around the world, especially those in low-and middle-income countries, have had to make difficult decisions related to the implementation and relaxation of lockdown measures.

Lockdown measures help to reduce transmission of the virus but have been associated with several secondary effects, including reduced livelihoods (Walker et al. 2020) , increased morbidity and mortality due to limited utilization of routine health services (Roberton et al. 2020), and several psychosocial and mental health implications (Roy et al. 2020) . Effective COVID-19 vaccines are viewed as one intervention that could alleviate the need for restrictive lockdown measures. Our model allowed us to make relative comparisons of COVID-19 vaccine allocation strategies in the context of various control measure scenarios. We found that the relative reduction in cases and deaths does not meaningfully change based on the level or absence of control measures when the vaccine does not provide sterilizing immunity. However, in the model where effective vaccines do provide sterilizing immunity, the relative reduction in cases and deaths is substantially greater when strong control measures are in place and minimizes the effect of vaccine dose availability.

In accordance with COVAX Facility requirements (World Health Organization 2020a), the allocation of COVID-19 vaccines to health care workers and social workers will need to be prioritized. There remains an acute health workforce shortage in many parts of the country (Rao et al. 2016; Shrivastava and Shrivastava 2019) . Immunizing this important population with priority, together with adequate supply of personal protective equipment, will help to strengthen the resiliency of the fragile health system during the epidemic. While health workers remain at higher risk of SARS-CoV-2 infection (Nguyen et al. 2020) , there is insufficient evidence to determine whether they contribute to transmission greater than other subgroups within any population. Our model, did not consider a health worker compartment and therefore does not make any assumptions about the contribution of this population to overall transmission of COVID-19 in India. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 With regard to the introduction of new health interventions, it is imperative to consider the experience of previous pandemics. During the 2009 H1N1 influenza pandemic, two issues that were raised were the need for accurate supply forecasts to inform vaccine ordering and subsequent distribution and the need for clear communication about priority groups for vaccination (Rambhia et al. 2010) . Population structure was an important factor in determining the optimal vaccine distribution (Lee et al. 2010; Matrajt and Longini Jr 2010) . Similarly, researchers have observed age-specific transmission dynamics and clinical features associated with SARS-CoV-2 Laxminarayan et al. 2020 ). Our age-structured model is able to account for these factors.

It has also traditionally been considered important that the elderly and those particularly vulnerable to infection (e.g., those with chronic respiratory diseases) be given priority while considering influenza vaccination strategies. However, targeting the elderly in vaccination policies has not maximally reduced influenza-related mortality rates (Baguelin et al. 2013) . Vaccine efficacy has also been found to decrease with age. A pooled analysis of vaccine efficacy over five influenza seasons among adults greater than 18 years who were systematically enrolled in the U.S. Flu Vaccine Efficacy Network showed that vaccine efficacy against A(H3N2) viruses was 14% (95% confidence interval [CI]: 14-36%) for adults ≥65 years versus 21% (95% CI: 9%-32%) for adults 18-49 years (Russell et al. 2018 ).

Vaccinating high transmission groups who tend to become infected more frequently, remain infected for longer, and therefore acting as vectors to bring the infection to the elderly had been found to be more successful (Baguelin et al. 2013) . However, adapting this to the COVID-19 scenario would depend on the immunogenicity and immune correlates of specific potential COVID-19 vaccines, which are currently unknown.

India has a robust national immunization program for early childhood that has been strengthened recently with demonstrable and striking gains in vaccination coverage (Gurnani et al. 2018 ). The recent introduction and rollout of the pneumococcal conjugate vaccine and rotavirus vaccine have shown that new vaccines can be successfully rolled out within existing public health infrastructure . While a clear strategy for childhood vaccination exists globally and in India, a . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236091 doi: medRxiv preprint blueprint for adult immunization is recognizably inadequate and is being increasingly acknowledged as important for sustaining and enhancing health outcomes, as well as social and economic outcomes is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 makes a number of key assumptions about transmission dynamics. Infection was assumed to provide temporary immunity against reinfection for one year, with other values explored in the supplemental materials. The actual average length of immunity due to COVID-19 infection is not precisely known and likely varies based on infection severity (Randolph and Barreiro 2020; van der Heide 2020; Wajnberg et al. 2020) . Many model parameters, such as force of infection, latent period, time to recovery, and vaccine efficacy all likely vary with age, and potentially with time. However, given lack of clear data, these factors were assumed constant. In addition, due to data availability, deaths were estimated using case fatality ratios and not infection fatality ratios, under the assumption that discrepancies between case and infection fatality ratios are predominantly due to undetected asymptomatic infections.

Within the model, vaccines were distributed to a target coverage level, which was constant for each age group. For practical implementation, certain age groups will likely be easier to reach and less reticent to vaccination than others, meaning true coverage may vary by age (Cobos Muñoz et al. 2015) . Preliminary evidence suggests that COVID-19 may be subject to seasonal forcing (Sajadi et al. 2020 ). This was not accounted for in the model to lack of a clear timeline for when vaccine rollout would begin. Given current understanding of COVID-19 immunity dynamic, there will likely be some prevalence of infection-driven immunity that exists before vaccine rollout begins. However, given uncertainties associated with vaccine delivery timelines, expected seroprevalence estimates, and the quality and duration of immunity from natural infection, there is no reliable data to inform this within the model. As a result, no prior immunity within the population was assumed. More broadly, this model was designed for comparison between vaccination strategies, and is not meant provide exact estimates of cumulative deaths or symptomatic infections. Rather results are meant to represent the estimated relative benefit of different scenarios.

Progress towards development and approval of SARS-CoV-2 vaccines has been extraordinarily fast, however challenges of fair and optimal allocation remain. Supply limitations and logistic challenges . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 suggest that vaccine administration across India will be slow, necessitating distribution strategies which offer the greatest protection. Within this study we have illustrated that when accounting for Indian population structure, vaccination of older age groups (>60yrs old) consistently provides the greatest reduction in cumulative deaths. Prioritized vaccination of younger age groups was often seen to reduce symptomatic infection rates, but this benefit was typically offset by the much larger infection fatality rates in older populations. Prioritized vaccination of older populations was seen to be optimal regardless of vaccine efficacy, dispensation speed, force of infection and target coverage, and independent of whether non-pharmaceutical interventions were implemented.

The authors report no conflicts of interest.

No funding or other support was received for this work.

CB conceptualized the project and collated the data. BF and BW developed the model and developed the code. BF prepared the visualizations. All authors contributed to the design of the model, the interpretation of the results, and the initial draft of the manuscript.

No human subjects were involved in this work and therefore ethical approvals were not required for the development of this manuscript.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236091 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236091 doi: medRxiv preprint

Subjects may move from susceptible to exposed to symptomatic or asymptomatic infectious.

Asymptomatic infectious are assumed to always recover, while symptomatic infectious first quarantine, before recovering or dying and (if recovered) eventually losing immunity. Each major compartment comprises eight sub-compartments, comprising age groups (0-10, 10-20, […] 60-70, ≥70 years). Rates of symptomatic infection ( ) and death ( ) vary by age group. Contact between susceptible and infectious populations is age-structured, proportional to the estimated contact pattern matrix ( ). Under a progressive rollout scheme, individuals are vaccinated each week, at an efficacy of . If the vaccine confers non-sterilizing immunity, individuals can become exposed and develop asymptomatic infections, before recovering and eventually losing infection-driven immunity.

For those vaccines that do not confer sterilizing immunity, 2 = 0; meaning vaccinated individuals no longer contribute to transmission dynamics.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236091 doi: medRxiv preprint

Each simulation assumed that 3% of the population was vaccinated each month, with a vaccine efficacy of 75%, no control measures, and an 0 of 2.4.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236091 doi: medRxiv preprint Figure 3 : Comparison of benefit for four different vaccination strategies, against no vaccination.

The relative reduction in deaths (A, B) and symptomatic infections (C, D) over a 5-year period are presented for four vaccination strategies, under varying speeds of vaccine dispensation. Results are stratified using three different vaccine efficacies, three types of control measure policy, and assuming a vaccine grants either sterilizing or non-sterilizing immunity. All simulations assumed vaccination did not exceed a population coverage of 75% and used an 0 of 2.4. Baseline deaths were calculated assuming no control measures and the same R0 value.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10.1101/2020.11.22.20236091 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 24, 2020. ; https://doi.org/10. 1101 

Google COVID-19 Community Mobility Reports: Anonymization Process Description (version 1.0) arXiv preprint

Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study PLoS medicine

Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study The Lancet Infectious diseases

COVID vaccine excitement builds as Moderna reports third positive result

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Exposing concerns about vaccination in low-and middle-income countries: a systematic review

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates The

Age-dependent effects in the transmission and control of COVID-19 epidemics

An interactive web-based dashboard to track COVID-19 in real time The

Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment measures

Framework for equitable allocation of COVID-19 vaccine The National Academy Press

Rapid COVID-19 vaccine development

Transmission dynamics of the COVID-19 epidemic in India and modelling optimal lockdown exit strategies medRxiv:2020

Improving vaccination coverage in India: lessons from Intensified Mission Indradhanush, a cross-sectoral systems strengthening strategy

COVID-19 vaccine trials should seek worthwhile efficacy The Lancet

Effects of (Un)lockdown on COVID-19 transmission: A mathematical study of different phases in India medRxiv:2020

Adult vaccination in India: status and the way forward

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application Annals of Internal Medicine

Epidemiology and transmission dynamics of COVID-19 in two Indian states

A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic Vaccine

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia The

Introducing rotavirus vaccine in the Universal Immunization Programme in India: From evidence to policy to implementation Vaccine

Optimizing vaccine allocation at different points in time during an epidemic

Milken Institute (2020) COVID-19 Treatment and Vaccine Tracker

Who is at the highest risk from COVID-19 in India? Analysis of health, healthcare access, and socioeconomic indicators at the district level medRxiv

Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study

What can we expect from first-generation COVID-19 vaccines?

Projecting social contact matrices in 152 countries using contact surveys and demographic data

Archetype analysis of older adult immunization decision-making and implementation in 34 countries Vaccine

A global agenda for older adult immunization in the COVID-19 era: A roadmap for action Vaccine

Covid-19: India imposes lockdown for 21 days and cases rise

Mass vaccination for the 2009 H1N1 pandemic: approaches, challenges, and recommendations Biosecurity and bioterrorism: biodefense strategy, practice, and science

Composition and distribution of the health workforce in India: estimates based on data from the National Sample Survey WHO South

Coronavirus in India: Tracking country's first 50 COVID-19 cases; what numbers tell

Influenza vaccination in the Americas: Progress and challenges after the 2009 A(H1N1) influenza pandemic

Mental health implications of COVID-19 pandemic and its response in

Influenza vaccine effectiveness in older adults compared with younger adults over five seasons Vaccine

Temperature, Humidity, and Latitude Analysis to Estimate Potential Spread and Seasonality of Coronavirus Disease

High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 Emerging Infectious Disease journal

Assessment of lockdown effect in some states and overall India: A predictive mathematical study on COVID-19 outbreak Chaos

Lessons for COVID-19 Immunity from

Strengthening of the Health Workforce to Meet Sustainable Development Goals in India

The Lancet (2020) COVID-19 in India: the dangers of false optimism The Lancet

Neutralizing antibody response in mild COVID-19

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months Science

The impact of COVID-19 and strategies for mitigation and suppression in low-and middle-income countries

Main operational lessons learnt from the WHO pandemic influenza A(H1N1) vaccine deployment initiative. World Health Organization, Geneva World Health Organization (2020a) COVAX: Working for global equitable access to COVID-19 vaccines

World Health Organization (2020b) WHO Concept for fair access and equitable allocation of COVID-19 health products 2020

Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22

Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak